Pharmacokinetics of Oral Mycophenolate Mofetil in Dog: Bioavailability Studies and the Impact of Antibiotic Therapy

Biology of Blood and Marrow Transplantation

Volumn 12, Issue 12, 2006, Pages 1352-1354

  Lupu, Marilena ^a   McCune, Jeannine S ^b   Kuhr, Christian S ^b   Gooley, Theodore ^b   Storb, Rainer ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BIOSOL; CELLCEPT INTRAVENOUS; CELLCEPT ORAL SUSPENSION; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEOMYCIN; POLYMYXIN B;

AREA UNDER THE CURVE; BLOOD SAMPLING; DOG; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; IMMUNOSUPPRESSIVE TREATMENT; LETTER; NONHUMAN; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE;

ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DOGS; DRUG INTERACTIONS; ENTEROHEPATIC CIRCULATION; GASTROINTESTINAL TRACT; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, SUBCUTANEOUS; INTESTINAL ABSORPTION; MALE; MYCOPHENOLIC ACID; NEOMYCIN; POLYMYXIN B;

EID: 33845243551     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2006.07.009     Document Type: Letter

References (8)

1. Shaw L.M., Korecka M., Venkataramanan R., Goldberg L., Bloom R., and Brayman K.L. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies (review). Am J Transplant 3 (2003) 534-542
2. Nash R.A., Johnston L., Parker P., et al. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 11 (2005) 495-505
3. Giaccone L., McCune J.S., Maris M.B., et al. Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. Blood 106 (2005) 4381-4388
4. Jacobson P., Rogosheske J., Barker J.N., et al. Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation. Clin Pharmacol Ther 78 (2005) 486-500
5. Yu C., Seidel K., Nash R.A., et al. Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts. Blood 91 (1998) 2581-2587
6. Storb R., Yu C., Wagner J.L., et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 89 (1997) 3048-3054
7. Bullingham R.E., Nicholls A.J., and Kamm B.R. Clinical pharmacokinetics of mycophenolate mofetil (review). Clin Pharmacokinet 34 (1998) 429-455
8. Shaw L.M., Nawrocki A., Korecka M., Solari S., and Kang J. Using established immunosuppressant therapy effectively: lessons from the measurement of mycophenolic acid plasma concentrations (review). Ther Drug Monit 26 (2004) 347-351